Oncology

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naive and secretase-treated desmoid tumors.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlight the need for oncologists to recognize and address depression for patients with cancer.

Several differences arise between community oncology centers and institutional oncology centers regarding the tools available and requirements of patients with cancer.

Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Vanessa Almendro Navarro, PhD, MBA, outlined what she hopes to accomplish in her new role as chief commercialization officer at City of Hope.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

This section aims to enhance provider empathy, mitigate burnout, and center the patient’s lived experience within the rigorous framework of medical science.

Vanessa Almendro-Navarro, PhD, MBA, outlined her experience as a research fellow and how her clinical work may impact her new role at City of Hope.

Vanessa Almendro-Navarro, PhD, MBA, discussed her background as a fellow at Dana-Farber, as well as her experience as a life science executive.

Updated results from the TRIDENT-1 trial support repotrectinib as a new treatment option for those with NTRK fusion-positive advanced solid tumors.

The implementation of AI into radiomics may help predict the likelihood of response to therapies among patients undergoing breast cancer treatment.

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless,” according to Brandon Mancini, MD, MBA, FACRO.

Loaiza-Bonilla anticipates that AI-assisted EKG models could be cleared for use in risk stratification for receipt of surgery or drug use.

Global analysis data reveal that lung, stomach, and cervical cancers represent approximately half of preventable cancers.

A phase 1/2 trial will evaluate N17350 in patients with pretreated, advanced solid tumors, such as head and neck neoplasms, NSCLC, and melanoma, among others.

CancerNetwork spoke with Arturo Loaiza-Bonilla, MD, MSEd, FACP, regarding his insights about recent advancements for AI in oncology.

One of the lesser-known costs of undergoing cancer treatment is the loss of work opportunities, according to Loretta Nastoupil, MD.

Federal cuts to insurance and cancer research could reduce access to therapies and stifle progress when incidence is rising across many common cancers.

The acceptance of the application is based on phase 3 MANEUVER study findings, in which pimicotinib improved responses vs placebo in this group.

Opening dialogue and establishing connections across different oncology camps may enhance the use of integrative modalities and bolster patient outcomes.

Patient demands for efficacious regimens without sacrificing quality of life are driving a greater emphasis on managing and mitigating AEs in oncology.

Investigators will assess the safety and early activity of OTP-01 among patients in the US and Australia across approximately 20 centers.